Can HRT in early menopause cut heart disease risk?

ConclusionThis double-blind RCT found that women taking HRT less than six years after the menopause had slower artery wall thickening than those taking a placebo. This represented the main measure of atherosclerosis progression tested; other measures showed no difference, so the results were not as conclusive as they could have been. Women taking HRT 10 or more years after menopause also showed no difference in atherosclerosis progression compared with a placebo, further complicating the picture.An important limitation of this study is the lack of a patient relevant endpoint, such as cardiovascular events or mortality. Previous studies from the 1980s have indicated that hormone therapy is linked to a reduction in heart disease in postmenopausal women, but had problems in the design of the research. As subsequent research failed to support the idea that hormone therapy prevents heart disease, it will be important to have well-designed studies with clinical outcomes.The number of women in the study, its randomised double-blind design, and average follow-up of five years help to build confidence in the study. The main ambiguity is whether the differing rates of artery thickening observed here are big enough to have an impact on a person's risk of heart attack or stroke.  The differences of 0.0078mm versus 0.0044mm per year for placebo and HRT groups were statistically convincing, but it's much less clear if they are clinically important. The researchers themselves describe ...
Source: NHS News Feed - Category: Consumer Health News Tags: Heart/lungs Medication Source Type: news

Related Links:

ConclusionsOur small-scale experimental study, in which PanoptiqTM was used in the diagnosis of cases that were difficult to diagnose definitively by breast FNA, revealed a positive CB score by every reviewer and the representative diagnosis showed a significant CB. The study suggested that PanoptiqTM could be used for cytopathology consultation.
Source: Journal of the American Society of Cytopathology - Category: Cytology Source Type: research
Publication date: Available online 17 December 2018Source: Journal of Neuroscience MethodsAuthor(s): Armand Mensen, Andrea Pigorini, Laura Facchin, Cornelia Schöne, Sasha D'Ambrosio, Jasmine Jendoubi, Valeria Jaramillo, Kathrin Studer, Aleksandra Eberhard-Moscicka, Simone Sarasso, Antoine Adamantidis, René Müri, Reto Huber, Marcello Massimini, Claudio BassettiAbstractOur own experiences with disturbances to sleep demonstrate its crucial role in the recovery of cognitive functions. This importance is likely enhanced in the recovery from stroke; both in terms of its physiology and cognitive abilities. Decade...
Source: Journal of Neuroscience Methods - Category: Neuroscience Source Type: research
We report a case of an 11-year-old Moroccan boy with EVC syndrome and Dandy-Walker malformation. To our knowledge, this association has been previously reported in 3 patients in the literature. PMID: 30556660 [PubMed - in process]
Source: Pediatric Endocrinology Reviews - Category: Endocrinology Tags: Pediatr Endocrinol Rev Source Type: research
CONCLUSION: The frequency of DKA although stable, remains high and is associated with a worse evolution of the disease. PMID: 30556656 [PubMed - in process]
Source: Pediatric Endocrinology Reviews - Category: Endocrinology Tags: Pediatr Endocrinol Rev Source Type: research
CONCLUSIONS: In our study, dronedarone appears to be a good therapeutic option in the treatment of atrial fibrillation in patients with amiodarone-induced hyperthyroidism. However, long-term studies are needed to estimate the efficacy and toxicity of both drugs. PMID: 30556893 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
CONCLUSIONS: This variant of the APOA1 gene showed important effects on HDL-cholesterol, HOMA-IR and insulin resistance after DBP for 3 years. PMID: 30556889 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
miRNA-130a improves cardiac function by down-regulating TNF-α expression in a rat model of heart failure. Eur Rev Med Pharmacol Sci. 2018 Dec;22(23):8454-8461 Authors: Jiang YR, Du JY, Wang DD, Yang X Abstract OBJECTIVE: To investigate the effect of MicroRNA (miRNA)-130a on cardiac function and the expression of tumor necrosis factor-α (TNF-α) in rats with heart failure. MATERIALS AND METHODS: The rat heart failure model (n = 30) were established, then divided into miRNA-130a group, phosphate-buffer saline (PBS) group, rAAV9 group, and sham group (n = 10 in each group). Four weeks...
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
Authors: Liu B, Yang XF, Liang XP, Wang L, Shao MM, Han WX, Wu YH Abstract OBJECTIVE: To explore the expressions of miR-132 in patients with chronic hepatitis B, posthepatitic cirrhosis and hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC), and to investigate its possible mechanism affecting the function of the body. PATIENTS AND METHODS: Among 125 patients with HBV, there were 44 cases of chronic hepatitis, 42 cases of liver cirrhosis and 39 cases of liver cancer. Their liver function and HBV-deoxyribonucleic acid (HBV-DNA) viral load as well as the expressions of micro ribonucleic acid-132 (miR-1...
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
CONCLUSIONS: Our findings provide novel insights into the role of miR-3196 in breast cell proliferation and apoptosis. Meanwhile, this study suggests that miR-3196 can serve as a potential biomarker and therapeutic target for breast cancer. PMID: 30556879 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
CONCLUSIONS: We showed that miR-1179 was a tumor suppressor that may serve as a novel potential prognostic biomarker or molecular therapeutic target for BC. PMID: 30556878 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
More News: Aci-Jel | Calcium | Cancer | Cancer & Oncology | Cardiology | Cardiovascular | CT Scan | Diabetes | Endocrinology | Estradiol | Health | Heart | Heart Attack | Heart Disease | Hormonal Therapy | Hormone Replacement Therapy | Hormones | Men | Menopause | Oral Cancer | Ovarian Cancer | Ovaries | PET Scan | Science | Statistics | Stroke | Study | Ultrasound | Women